Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML

NEXT STORY
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in China for RECCE® Anti-Infectives
PREV STORY
Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Syndax Appoints Leading Experts to Scientific Advisory Board (SAB)

WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical ...

author_avatar
NASDAQ Market News

 Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital Partners 30th Annual Growth Stock Conference on 03/12/18

SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced ...

author_avatar
NASDAQ Market News

Software Veteran James Lim Joins Syapse as Senior Vice President of Product Development

Lim will lead development of the Syapse software platform to support precision medicine initiatives ...

author_avatar
NASDAQ Market News